MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
38.15
+0.30 (+0.79%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close37.85
Open37.70
Bid37.75 x 3000
Ask38.25 x 2200
Day's Range37.62 - 38.40
52 Week Range29.53 - 47.82
Volume3,220,677
Avg. Volume4,764,755
Market Cap19.669B
Beta1.38
PE Ratio (TTM)28.18
EPS (TTM)1.35
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-06-27
1y Target Est46.83
Trade prices are not sourced from all markets
  • The Wall Street Journal3 hours ago

    [$$] A Shot of Competition for EpiPen

    A couple of years ago Washington fell into anaphylactic shock over the high cost of EpiPens, devices that shoot adrenaline into someone having an allergic reaction. On Thursday the Food and Drug Administration approved the first generic competitor to Mylan’s EpiPen. The competing drug is manufactured by the Israeli pharmaceutical company Teva.

  • EpiPen Shortage 2018: 13 Things for Parents to Know
    InvestorPlace2 days ago

    EpiPen Shortage 2018: 13 Things for Parents to Know

    Here are a few things to know about the EpiPen shortage. The U.S. Food and Drug Administration has confirmed that there is in fact a shortage of EpiPens. The shortage has actually been going on for months, but is only kick up more dust lately as school starts.

  • Mylan’s EpiPen Supply Shortages Continue: What to Expect Ahead
    Market Realist3 days ago

    Mylan’s EpiPen Supply Shortages Continue: What to Expect Ahead

    Mylan’s (MYL) epinephrine auto-injector EpiPen is approved as the first line of treatment for life-threatening allergic reaction anaphylaxis. During its second-quarter earnings release on August 8, Mylan provided an update on its EpiPen supply shortages.

  • Lifesaving EpiPen Device Still Out of Stock at Many Pharmacies
    Bloomberg3 days ago

    Lifesaving EpiPen Device Still Out of Stock at Many Pharmacies

    Mylan NV’s EpiPen is still hard to find at many pharmacies, three months after U.S. authorities declared that the lifesaving allergy device was in shortage, a survey by Wells Fargo & Co. showed. The finding comes a day after Teva Pharmaceutical Industries Ltd. gained Food and Drug Administration approval to sell a generic version of Mylan’s epinephrine autoinjector. Wells Fargo analysts reached out to 53 pharmacies across the country on Thursday and found that 66 percent were out of stock of Mylan’s EpiPens, not including EpiPen Jr., analyst Davis Maris said in a note Friday.

  • Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic
    Zacks3 days ago

    Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic

    Mylan (MYL) suffers another setback as Teva wins the FDA approval of first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions.

  • Teva Gets FDA Nod for First Generic Version of Mylan's EpiPen
    Zacks3 days ago

    Teva Gets FDA Nod for First Generic Version of Mylan's EpiPen

    Teva (TEVA) gains FDA approval for the first generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment.

  • There’s an EpiPen shortage — and parents fear for their allergic kids
    MarketWatch3 days ago

    There’s an EpiPen shortage — and parents fear for their allergic kids

    Only after calling between eight and 10 pharmacies in her New Jersey area was Wachtler able to find a two-pack of the generic EpiPen — and it was the pharmacy’s last box. Mylan’s (MYL) brand-name EpiPen and the authorized generic, two widely used allergic reaction treatments, as well as Amneal Pharmaceuticals’ (AMRX) generic auto-injector Adrenaclick were added to the Food and Drug Administration’s drug shortage list in May. Another manufacturer, privately held Kaleo Inc., has not reported supply interruptions.

  • Mylan’s Q2 Profit Fell against Backdrop of US Market Dynamics
    Market Realist3 days ago

    Mylan’s Q2 Profit Fell against Backdrop of US Market Dynamics

    Mylan reported its second-quarter results on August 8. Mylan had completed a $1.0 billion share repurchase program at the beginning of 2018, the benefits of which are reflected in its adjusted EPS growth. In the second quarter, Mylan’s gross profit fell ~40% YoY to $962.5 million.

  • A Performance Overview of Bausch’s Diversified Products Business
    Market Realist3 days ago

    A Performance Overview of Bausch’s Diversified Products Business

    Bausch Health Companies’ (BHC) Diversified Products segment reported net revenue of $336 million in the second quarter compared to $461 million in the second quarter of 2017, a ~27% YoY (year-over-year) fall.

  • EpiPen shortage has parents struggling during back-to-school season
    CNBC3 days ago

    EpiPen shortage has parents struggling during back-to-school season

    The life-saving allergy medicine has had manufacturing disruptions since May, but allergy sufferers and caregivers may find it especially hard to find now, as parents try to stock up to send their kids back to school.

  • ACCESSWIRE3 days ago

    Today’s Research Reports on Stocks to Watch: Teva Pharmaceutical and Mylan

    NEW YORK, NY / ACCESSWIRE / August 17, 2018 / Shares of Teva jumped on Thursday after gaining FDA approval for its generic version of the EpiPen and announcing positive data results on its Fasinumab drug ...

  • Mylan’s Morgantown Restructuring and Remediation Program
    Market Realist3 days ago

    Mylan’s Morgantown Restructuring and Remediation Program

    For the second quarter, Mylan (MYL) recorded expenses of $87 million related to the restructuring and remediation program it undertook in the quarter for its flagship Morgantown, West Virginia, facility. According to Mylan, the program is aimed at reducing the complexities at the facility and simplifying the operations.

  • Financial Times3 days ago

    [$$] FirstFT: Today’s top stories

    Whistleblower protections at Royal Bank of Canada are under scrutiny. The UK’s Financial Conduct Authority is investigating after a former trader at Canada’s biggest bank won his case for unfair dismissal and at least five more potentially similar cases came to light. The London-based RBC staff involved claim to have been dismissed without due process after highlighting legal and compliance problems across a range of businesses in cases spanning several years, multiple people familiar with the matter told the Financial Times.

  • The Wall Street Journal3 days ago

    FDA Approves Teva’s Generic Version of EpiPen Injector

    WASHINGTON—The Food and Drug Administration approved Teva Pharmaceutical Industries Ltd.’s generic version of Mylan’s EpiPen injector device for life-threatening allergic reactions, the most widely sold such device in the U.S. The product, whose brand-name version is manufactured by Mylan NV, touched off a furor two years ago over its price increases of 548% over about a decade. Mylan introduced its own half-priced generic version of the drug in 2016.

  • Associated Press3 days ago

    US approves new generic competitor to EpiPen

    WASHINGTON (AP) — U.S. health officials on Thursday approved a new generic version of EpiPen, the emergency allergy medication that triggered a public backlash due to its rising price tag.

  • FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%
    Market Realist3 days ago

    FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%

    Today, Teva Pharmaceutical Industries (TEVA) received FDA approval for the generic version of Mylan’s (MYL) allergy products EpiPen and EpiPen Jr. The epinephrine autoinjector is used to treat allergic reactions, including life-threatening condition of anaphylaxis. The company received FDA approval for the use of the product in adults as well as children weighing more than 33 pounds. In 2016, Teva’s generic version of EpiPen was unable to secure FDA approval.

  • Why Symantec, Teva Pharmaceutical Industries, and Century Aluminum Jumped Today
    Motley Fool3 days ago

    Why Symantec, Teva Pharmaceutical Industries, and Century Aluminum Jumped Today

    Find out how the latest trade news helped one of these stocks.

  • TheStreet.com3 days ago

    Teva Notches Win With FDA Approval of Generic EpiPen

    The U.S. Food and Drug Administration has given Teva Pharmaceutical Industries Ltd.'s a shot in the arm. Teva's American depositary receipts shot up on Thursday, Aug. 16, after the FDA approved a generic version of Mylan NV's EpiPen auto-injector for treating allergic reactions.

  • Benzinga3 days ago

    Teva Wins FDA Approval For Generic Epinephrine

    After nearly two years, the U.S. Food & Drug Administration has finally approved the generic versions of the EpiPen produced by Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA). What Happened? On Thursday, the FDA approved Teva's generic versions of the EpiPen and EpiPen Jr. epinephrine auto-injectors for patients with severe allergies.

  • Reuters3 days ago

    U.S. FDA approves first generic of Mylan's EpiPen

    U.S.-listed shares of Teva jumped 6 percent to $23.88, while Mylan shares were down 0.64 percent. Mylan had come under intense regulatory and political scrutiny in the last few years due to escalating price of EpiPen amid lack of competition. EpiPen is intended to automatically inject a dose of epinephrine, also known as adrenaline, into a person's thigh to stop an allergic reaction.

  • Reuters3 days ago

    U.S. FDA approves first generic of Mylan's EpiPen

    U.S.-listed shares of Teva jumped 6 percent to $23.88, while Mylan shares were down 0.64 percent. Mylan had come under intense regulatory and political scrutiny in the last few years due to escalating price of EpiPen amid lack of competition. EpiPen is intended to automatically inject a dose of epinephrine, also known as adrenaline, into a person's thigh to stop an allergic reaction.

  • Reuters3 days ago

    U.S. FDA approves first generic of Mylan's EpiPen

    U.S. health regulators on Thursday approved Teva Pharmaceutical Industries Ltd's generic of Mylan NV's EpiPen, making it the first copycat version of the life-saving allergy treatment. U.S.-listed shares of Teva jumped 6 percent to $23.88, while Mylan shares were down 0.64 percent. Mylan had come under intense regulatory and political scrutiny in the last few years due to escalating price of EpiPen amid lack of competition.

  • MarketWatch3 days ago

    FDA approves first rival generic EpiPen, sending Teva shares up 6%

    Shares of the U.S.-listed Teva Pharmaceutical Industries Ltd. (TEVA) surged 6.2% in extremely heavy Thursday afternoon trade after the company's generic version of the EpiPen allergic reaction treatment was approved by the Food and Drug Administration, making it the product's first true generic rival. Teva secured approval for both adult and child-appropriate dose levels of its generic epinephrine autoinjector. Shares of Mylan (MYL) , which sells the EpiPen and a cheaper authorized generic version, slumped 0.5% in heavy trade, while rivals Amneal Pharmaceuticals Inc. (AMRX) and Adamis Pharmaceuticals Corp. (ADMP) had shares drop 3% and 7.5% respectively.

  • EpiPen Gets First Generic Rival After Furor Over High Price
    Bloomberg3 days ago

    EpiPen Gets First Generic Rival After Furor Over High Price

    EpiPen, a life-saving allergy treatment widely criticized for its high price tag, will get generic competition for the first time since the autoinjector was approved more than two decades ago. The Food and Drug Administration on Thursday cleared Teva Pharmaceutical Industries Ltd.’s generic EpiPen and EpiPen Jr. for sale, several years after the Israeli drugmaker filed for approval. Mylan NV has attempted to thwart competition from Teva, claiming that differences in how the epinephrine-injecting devices work would confuse patients.

  • CNBC3 days ago

    FDA approves Teva’s generic EpiPen after yearslong delay

    Teva Pharmaceuticals received Food and Drug Administration approval for generic versions of both the EpiPen and EpiPen Jr. The products will be the first generic competitor to EpiPen. Mylan, the maker of the EpiPen, introduced its own authorized generic version in late 2016. Mylan was criticized after the public learned the price of the emergency allergy drug rose more than 400 percent over a decade.